Relative saccade amplitude distribution. by Junhui Kim (18575083)

Subjects:

The proportion of participants who reported authorship (self, delay, or other). by Junhui Kim (18575083)

Subjects:

Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration-3 by Sergio Liarte (75701)

“…<p><b>Copyright information:</b></p><p>Taken from "Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration"</p><p>http://www.rbej.com/content/5/1/20</p><p>Reproductive Biology and Endocrinology 2007;5():20-20.…”

Signal Amplification for Cell-Free Biosensors, an Analog-to-Digital Converter by Rafael A. L. Franco (17094315)

“…The serine integrase circuit efficiently contained leakage, boosted the expression fold change from OFF to ON, and decreased the detection limit of the switches by 3–4 orders of magnitude. …”

Signal Amplification for Cell-Free Biosensors, an Analog-to-Digital Converter by Rafael A. L. Franco (17094315)

“…The serine integrase circuit efficiently contained leakage, boosted the expression fold change from OFF to ON, and decreased the detection limit of the switches by 3–4 orders of magnitude. …”

Signal Amplification for Cell-Free Biosensors, an Analog-to-Digital Converter by Rafael A. L. Franco (17094315)

“…The serine integrase circuit efficiently contained leakage, boosted the expression fold change from OFF to ON, and decreased the detection limit of the switches by 3–4 orders of magnitude. …”

Fig 2 - by Jung-Kwon Bae (11432672)

Depletion of TPX2 causes defects in 53BP1 ionizing radiation-induced foci formation. by Gernot Neumayer (77179)

“…TPX2 miRNA (37.2+/−4.5), p<0.001, n = 20; 4 h: control (57.5+/−5.0) vs. …”

Table_5_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

“…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”

Key safety measures including adverse events. by Anuja Dokras (8679261)

“…A total of 169 participants (70.4%) completed the trial between January 2018 and June 2023 (mean age: 29.5 years; mean BMI: 35.6 kg/m²; 70% were White and 23% were Black). …”

Averaged first slice of second-order kernel of the mfERGs of the nasal hemisphere within the central 7.5° for different stages of glaucoma (Blue trace: Advanced stage, Brown trace:... by Naoya Moroto (14419705)

Boxplots showing the differences in miR-21-5p and miR-16-5p levels across increasing AKI severity based on Kidney Disease: Improving Global Outcomes (KDIGO) grades. by Tamar J. van der Aart (22184206)

Fluorescent intensity at 520 nm (RNase A/B) and 556 nm (DNase I) versus time for nucleases in DI water lysed with Lyse-It at 30% and 50% power for varying time. by Tonya M. Santaus (5559077)

Proliferation rates of Vasa2+/Piwi1+ were independent on the daytime of the sampling, and mitotic rates were not significantly different upon refeeding of 5- or 20-day-starved poly... by Eudald Pascual-Carreras (12115380)

Subcellular levels of p53 protein in hTCEpi-TR cell lines. by Vindhya Koppaka (845151)

Brain uptake rate of [¹⁴C]docosahexaenoic acid (DHA) in the whole brain and each brain region. by Takuro Iwao (14636741)

Brain uptake rate of [¹⁴C]sucrose in the whole brain and individual brain regions. by Takuro Iwao (14636741)

Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”